Trial Profile
A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemotherapy for the First Line Treatment for Patients With Advanced Biliary Tract Cancers (TOURMALINE)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 17 Apr 2024
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Durvalumab (Primary) ; Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary)
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Adverse reactions; Registrational
- Acronyms TOURMALINE
- Sponsors AstraZeneca
- 27 Nov 2023 Planned number of patients changed from 160 to 140.
- 27 Nov 2023 Planned End Date changed from 31 Mar 2026 to 17 Mar 2026.
- 27 Nov 2023 Planned primary completion date changed from 31 Mar 2026 to 17 Sep 2025.